Next Article in Journal
Male Oncology Research and Education Program for Men at High Risk for Prostate Cancer
Previous Article in Journal
Connecting People with Cancer to Physical Activity and Exercise Programs: A Pathway to Create Accessibility and Engagement
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 25
Issue 2
10.3747/co.25.4044
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Evidence-Based Best Practices for EGFR T790M Testing in Lung Cancer in Canada

by
T. Stockley
1,*,†,
C. A. Souza
2,
P. K. Cheema
3,
B. Melosky
4,
S. Kamel-Reid
1,5,
M. S. Tsao
6,
A. Spatz
7 and
A. Karsan
8,*,†
1
University Health Network, 11-454 Eaton Wing, Toronto General Hospital, 200 Elizabeth Street, Toronto, ON M5G 2C4, Canada
2
Department of Medical Imaging, The Ottawa Hospital, Ottawa, ON K1Y 4E9, Canada
3
Department of Medicine, University of Toronto, Toronto, ON M5S, Canada
4
Department of Oncology, BC Cancer, Vancouver, BC V5Z 4E6, Canada
5
Department of Medical Biophysics, University of Toronto, Toronto, ON M5S, Canada
6
Princess Margaret Cancer Centre, Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON M5S, Canada
7
Department of Pathology, McGill University, Montreal, QC H3A 0G4, Canada
8
Michael Smith Genome Sciences Centre, BC Cancer Research Centre, 675 West 10th Avenue, Vancouver, BC V5Z 1L3, Canada
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to the present work.
Curr. Oncol. 2018, 25(2), 163-169; https://doi.org/10.3747/co.25.4044
Submission received: 4 January 2018 / Revised: 5 February 2018 / Accepted: 13 March 2018 / Published: 1 April 2018

Abstract

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIS) are recommended as first-line systemic therapy for patients with non-small-cell lung cancer (NSCLC) having mutations in the EGFR gene. Resistance to TKIS eventually occurs in all nsclc patients treated with such drugs. In patients with resistance to TKIS caused by the EGFR T790M mutation, the third-generation TKI osimertinib is now the standard of care. For optimal patient management, accurate EGFR T790M testing is required. A multidisciplinary working group of pathologists, laboratory medicine specialists, medical oncologists, a respirologist, and a thoracic radiologist from across Canada was convened to discuss best practices for EGFR T790M mutation testing in Canada. The group made recommendations in the areas of the testing algorithm and the pre-analytic, analytic, and post-analytic aspects of clinical testing for both tissue testing and liquid biopsy circulating tumour DNA testing. The recommendations aim to improve EGFR T790M testing in Canada and to thereby improve patient care.
Keywords: non-small-cell lung cancer; NSCLC; epidermal growth factor receptor; EGFR T790M; cell-free tumour DNA; ctDNA non-small-cell lung cancer; NSCLC; epidermal growth factor receptor; EGFR T790M; cell-free tumour DNA; ctDNA

Share and Cite

MDPI and ACS Style

Stockley, T.; Souza, C.A.; Cheema, P.K.; Melosky, B.; Kamel-Reid, S.; Tsao, M.S.; Spatz, A.; Karsan, A. Evidence-Based Best Practices for EGFR T790M Testing in Lung Cancer in Canada. Curr. Oncol. 2018, 25, 163-169. https://doi.org/10.3747/co.25.4044

AMA Style

Stockley T, Souza CA, Cheema PK, Melosky B, Kamel-Reid S, Tsao MS, Spatz A, Karsan A. Evidence-Based Best Practices for EGFR T790M Testing in Lung Cancer in Canada. Current Oncology. 2018; 25(2):163-169. https://doi.org/10.3747/co.25.4044

Chicago/Turabian Style

Stockley, T., C. A. Souza, P. K. Cheema, B. Melosky, S. Kamel-Reid, M. S. Tsao, A. Spatz, and A. Karsan. 2018. "Evidence-Based Best Practices for EGFR T790M Testing in Lung Cancer in Canada" Current Oncology 25, no. 2: 163-169. https://doi.org/10.3747/co.25.4044

APA Style

Stockley, T., Souza, C. A., Cheema, P. K., Melosky, B., Kamel-Reid, S., Tsao, M. S., Spatz, A., & Karsan, A. (2018). Evidence-Based Best Practices for EGFR T790M Testing in Lung Cancer in Canada. Current Oncology, 25(2), 163-169. https://doi.org/10.3747/co.25.4044

Article Metrics

Back to TopTop